According to the market research firm Emergent Research, international cell and gene therapy companies could generate $6.6 billion in revenue by 2027, with a projected CAGR of 19.8% from 2020 to 2027. Waiting in the wings is Pfizer, whose DMD hopeful PF-06939926encountereda roadblock in late 2021 after a treated patient died. AAV-based gene therapies for x-linked myotubular myopathy (XLMTM), Pompe disease, Duchenne muscular dystrophy and myotonic dystrophy. The company is using a stem cell biology and genomics platform to develop a novel autologous induced pluripotent stem cell (iPSC)-derived neuron replacement therapy for Parkinsons Disease. Justin has decades of neuromuscular disease research & developed Biglycan as a potential therapy for DMD. The FDA has granted May 29, 2023, as the action date for the companys biologics license application (BLA) for accelerated approval of SRP-9001 for treating Now, after serving three years in a Chinese prison for practicing medicine without a license, he faces obstacles and critics as he tries to re-enter science. James is an expert in CMC drug development, with decades of experience in the Pharmaceutical industry. HuCo kidney, HuCo heart, HuCo islet cells, HuCo liver perfusion. These results have paved the way for ongoing human trials, which have shown a promising ability of this therapy to slow the progression of the disease. Now that the dystrophy gene was brought down to a useful size, the next challenge researchers faced was getting the gene therapy from the blood stream into the muscle. FDA Approves BeiGenes Brukinsa for CLL/SLL BeiGene's Brukinsa (zanubrutinib) for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) has been approved by the US Food and Drug Administration. Novartis is a Swiss multinational pharmaceutical company that has been involved in gene therapy research since the 1990s. The company specializes in the use of AI to build novel genetic therapies. AAVs are also common viruses some people have already been exposed to AAVs naturally and would never know because they cause no symptoms. Among the EU5 countries, the UK had the highest prevalent population of DMD with more than 2K cases, while Spain had the lowest DMD cases in 2020. Corticosteroids help dampen down inflammation, said Hesterlee. Subsequent gene therapy trials have moved to intravenous (IV) administration typically only requiring one fairly quick dose. Regardless, Pfizer will need to examine the situation and acquire the data necessary to continue the Phase Ib trial and make changes to future trials, such as omitting certain mutation types. We have developed a Platform Technology with key features to address the problems posed by AAV administration; Our technology does not use viruses to deliver genes to the cells. https://www.alliedmarketresearch.com/request-sample/2841. Successful introduction of gene therapy to treat DMD will require careful planning, education, capacity building and prioritization of core i Specializing in CRISPR/Cas9 technology, CRISPR Therapeutics is initially targeting the blood diseases -thalassemia and sickle cell disease. Specializes in developing next-generation AAV capsids for gene therapies. The company has a variety of in vivo and cell therapy programs for indications including hemophilia A and various tumors. Moreover, the companies are hoping that their Duchenne Muscular Dystrophy treatment will slow or even stop disease progression, giving patients a chance to avoid the devastating effects of Duchenne. Another component provides stability in the circulation and assists in movement from blood vessels to the muscle. Gene therapy replaces the mutated gene with a copy using whats called a vector to bring a working copy of the gene into a cell. Click for Index WebDMD gene therapy aims to deliver a working version of the dystrophin gene, so that the body can produce functioning dystrophin. This news closes a tumultuous time for Astellas regarding the therapy. Patients with this form of the muscle-wasting disease don't make enough dystrophin, a protein involved in muscle strength. Sarepta is currently the leading gene therapy player in the DMD space. Sarepta Therapeutics (Sarepta) discovers and develops unique RNA-targeted medicines to treat rare diseases. Both employ exon skipping, redirecting DNA processing inside the muscle cells to create minidystrophin right in the cells much like the researchers did in the lab, but directly in the children themselves. Despite this progress, most DMD patients pass away in their 20s to 30s due to respiratory failure, infection, or cardiomyopathy (dilation of the heart due to overwork). On the other hand, high cost of gene therapies restrains the growth to some extent. However, gene therapy for Duchenne muscular dystrophy still has several hurdles to overcome. The biotech specializes in creating gene therapies for severe genetic disorders and cancer. Byrne and colleagues now had a therapeutic that would fit in the AAV. In April, due to drug development challenges and fraught economic circumstances, the company wasforcedto slash its workforce by 35%. Gene therapies are a promising treatment option, and a recent study published in Science Translational Medicine describes success with one such therapy using an animal model. There are currently four companies who have DMD gene therapy products that have been given to boys with Duchenne, and three of the companies have ongoing studies in the USA. Matthew is a trained Cardiologist with a Ph.D. in cardiovascular physiology. Duchenne Muscular Dystrophy is caused by a dystrophin gene mutation (a protein in the muscles). They also have 12 other exon skipping-based genetic medicines in their pipeline. As per DelveInsight Duchenne Muscular Dystrophy Epidemiology Report, the total DMD prevalent population was more than 30K in the 7MM in 2020, which is further expected to increase by 2032. WebGene therapy is under development for the treatment of Duchenne muscular dystrophy. Extensive pre-clinical evidence also formed part of the BLA. Researchers are trying to ensure that enough gene therapy product was delivered to muscle tissue to have an effect. solutions for life science vertical and offering quintessential advisory services in the WebDespite scientific discoveries in the field of gene and cell therapy, some diseases still have no effective treatment. Check out the MDAs Facebook Live Q&A event MDA Frontline COVID-19 Response: Back-to-School in the Midst of COVID-19 Concerns for the Neuromuscular Disease Community with Dr. Christopher Rosa and Justin Moy. Tune in live this Friday, July 31 at 3pm ET to join the discussion. The whole 2.2 Mb dystrophin gene over 440 times as big is too large to fit inside any AAV. GALGT2 is a gene which is transferred in body with adeno-associated virus (AAV) vector (rAAVrh74.MCK). Gene therapies are particularly enticing for conditions involving a single gene mutation, like this. Scientists leverage this by removing the viral genes and inserting a working copy of the patients mutated gene. That allowed researchers to test the gene therapy proof-of-concept in DMD patients without worrying about systemic administration right off the bat. Companies focusing on DMD gene therapies have proceeded cautiously after a fatal case of myocarditis was observed in Pfizers gene therapy candidate. Although we now know DMD is a genetic disease, it wasnt that long ago that researchers didnt know why or how the disease came about. Sarepta is also conducting a Phase 3 clinical trial called EMBARK to further test SRP-9001s safety and efficacy. This fact and the use of an AAV vector which has a tendency to accumulate in skeletal and heart muscle justified a larger trial. The Phase, I/II trial, named AFFINITY DUCHENNE study, which is set to begin in the coming months. The company has multiple cell therapy candidates in pre-clinical and clinical development. While AAV vectors work great for delivering gene therapies to muscle cells, as Barry Byrne, co-author of the new study and professor of pediatrics at the University of Florida, explained, they have a size limitation. He is currently a Professor of Physiology and Biophysics at the University of Washington. This designation is designed to provide regulatory assistance and financial benefits to the therapys clinical research and evaluation, as well as a seven-year period of marketing exclusivity in the United States after regulatory clearance. Sarepta Therapeutics obtains positive preliminary phase 1/2a results for patients with DMD using its gene therapy product. This may lead to dangerous side effects. The hold was lifted in Aprilafter Pfizer addressed the Agencys concerns. UCART123, UCART22, UCARTCS1, UCART19, ALLO-501, ALLO-715. (read more) December 14, 2022 Publication: Genethon helps clarify a molecular mechanism of mitochondrial malfunction in Duchenne But it took another 30 years to be able to apply this knowledge to develop effective drugs., Although corticosteroids can slow the progression of DMD to some extent, they dont address the underlying issue the lack of functional dystrophin. Which Countries Top the Chart in Global Pharmaceutical Market? SRP-9001: Stan was elected to the Washington State Academy of Sciences in 2013 and selected as a Fellow of the American Association for the Advancement of Sciences in 2017. Top 10 Companies Of Gene Therapy According to Allied Market Research By its Revenue 1. A Range of Possible Mechanisms. The gene editing company focuses on diseases for patients with serious diseases. DMD starts to show its effects during early childhood. The biotech aims to engineer precision genetic medicine for rare diseases. Were still learning from human studies, it just shows that not every model will be predictive of the human clinical finding, he said. GALGT2 (Nationwide Childrens) is under clinical development by Sarepta Therapeutics and currently in Phase II for Duchenne Muscular Dystrophy. Our list of prominent cell and gene therapy companies includes top-tier Big Pharma companies as well as smaller privately-held companies. The boys motor functions rapidly deteriorate with disease progression and, by only 10 to 15 years of age, many boys with DMD are wheelchair-bound. The FDA hasacceptedSarepta'sBiologic License Application for the accelerated approval of SRP-9001 (delandistrogene moxeparvovec), an investigational gene therapy for Duchenne Muscular Dystrophy (DMD). The company sells a variety of instruments and consumables. It is difficult and costly to manufacture large quantities of AAV. Solid Biosciences therapy, called SGT-001, involves a microdystrophin gene carried by an AAV9 viral vector. Focusing on developing therapeutics for disorders of the central nervous system. The Agency has also granted the companies priority review and set the regulatory action date for May 29, 2023. Eventually the heart and breathing muscles are compromised, leading to a premature death from heart or respiratory failure. Our Platform Technology consists of proprietary components that are designed to stabilize and effectively deliver full-length genes into muscles. of R&D, Strategy Formulation, According to data from Solids clinical program, SGT-001 has the potential to slow or stop the Duchenne progression, regardless of genetic mutation or disease stage. Duchenne Muscular Dystrophy (DMD) is a rare disorder, but it is one of the most common genetic conditions, affecting roughly 1 in every 3,500 male births worldwide. The first U.S. human gene therapy trial directed at Duchenne muscular dystrophy (DMD) was launched yesterday at Columbus (Ohio) Sarepta is the only company with three FDA-approved DMD drugs in its commercial portfolio. This explains why it largely affects boys as they dont have a backup copy of the gene (they only have one X chromosome). Microdystrophin expression was seen via muscle biopsies 90 days after treatment (at a dose of 2E14 vg/kg), which stabilized dystrophin-associated proteins and restored activity of a key enzyme (called neuronal nitric oxide synthase, or nNOS) in the muscles. FDA Approved: December 12, 2019; Company: Sarepta Therapeutics WebGene therapy Cell therapy Drug therapy Mutation specific approaches About clinical research Current trials in DMD Current trials in SMA Current trials in LGMD Facing the Challenges of Clinical Trials Overview of therapeutic approaches for SMA The Problem The splicing process Therapeutic strategies for SMA Outcome measures July 6, 2022. Viltepso is an antisense oliogonucleotide indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. The drug in question, GS-1811 (formerl AbbVie Secures Fourth FDA Approval for Vraylar AbbVie has received its fourth FDA approval for Vraylar, adding major depressive disorder (MDD) adjunctive therapy to a list that includes schizophrenia and manic and depressive episodes in bipolar disorder. Pfizers PF-06939926 was designated as an Orphan Drug and Pediatric Rare Disease by the FDA in May 2017 and an Orphan Medicinal Product Designation by the EMA for the treatment of DMD. These findings showed a significant improvement in patient-reported outcomes and provided encouraging evidence of functional benefit 1.5 years after treatment when compared to natural history data. All Rights Reserved. They finally found the perfect balance, naming the shortened genes microdystrophins.. The pharma and biotech editor of WTWH Media, Brian is a veteran journalist with more than 15 years of experience covering an array of life science topics, including clinical trials, drug discovery and development and medical devices. Gene therapy is under development for the treatment of Duchenne muscular dystrophy. He has extensive research experience in DMD. By Chelsea Weidman Burke. CLL is a common type of leukemia, accounting for approximately 25% of all new cases each year. Gene therapy is an umbrella term for a range of therapies that target the genetic underpinnings of disease. Throughout the late 1990s and early 2000s, researchers tinkered with the dystrophin gene, figuring out what parts were needed and how much they could trim out to still have a functional protein. All rights reserved. GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. Once inside the cell, the viral vector behaves like a virus and makes the cell produce the protein encoded by the working gene it is carrying, compensating for the original mutated copy. They can help slow down disease progression, but tackling inflammation only addresses one downstream effect.. Graphite Bio is building on CRISPR technology and working with the cells natural DNA repair processes to rewrite genes. As a recessive, X-linked condition, it almost exclusively affects males with approximately 200,000 individuals affected worldwide. 1985 - 2023 BioSpace.com. Credit: Shutterstock, Engineering Natural Killer Cells for Cancer Immunotherapy [Video], Targeting the untargetable and treating the untreatable, Neural networks overcome the setbacks of current computational drug discovery, Copyright 1999-2023 John Wiley & Sons, Inc. All rights reserved. RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, RGX-381. Email (801) 436-5597. SGT-001 is based on groundbreaking dystrophin biology research conducted by researchers at the University of Washington and the University of Missouri. As part of the FDA's accelerated approval pathway, Roche and Sarepta have also initiated the EMBARK trial, a global, randomized, double-blinded and placebo-controlled study of SRP-9001 in DMD patients aged 4 to 7 years old. It has a pipeline of in vivo and ex vivo therapies. DMD is the most frequent type of muscular dystrophy that develops in childhood and primarily affects men. Today, many AAV-based gene therapy medications are Also, many people already have preexisting immunity to AAV, which may prevent them from ever receiving this gene therapy. WebHigh cost of Duchenne muscular dystrophy treatment. Cellectis has more than two decades of experience in gene editing. Duchenne muscular dystrophy (DMD) is a severe genetic disorder characterized by progressive muscle degeneration and consequent muscle weakness. Gene therapy is more efficient and covers everyone, regardless of genetic mutations, but its still good to have options while new therapies are in development.. In addition, RNA has potential in treating brain cancer, asMass General Brighamobserves in its list of one dozen potentially disruptive cell and gene therapy innovations. Connect with him on LinkedIn or email at [emailprotected], Copyright 2023 WTWH Media LLC. The therapeutic landscape: DMD is caused by mutations the largest known human gene, which encodes a protein called dystrophin. According to Solids leadership, this would allow it to focus on two other key DMD programs. The participants who were initially given SRP-9001 will then receive a placebo infusion, followed by another year of monitoring. A number of companies are now testing their approaches in the clinic. But we were cautious after the high profile death of Jesse Gelsinger in 1999.. The companys core focus areas include immuno-oncology and plant sciences. All rights reserved. For dogs receiving the treatment, there was an increase in microdystrophin protein in skeletal and heart muscle as well as the diaphragm. A severe genetic disorder characterized by progressive muscle degeneration and consequent muscle weakness participants... Unique RNA-targeted medicines to treat rare diseases the Chart in Global Pharmaceutical Market, UCART19, ALLO-501 ALLO-715... Therapy proof-of-concept in DMD patients without worrying about systemic administration right off the bat a of!, 2023 Chart in Global Pharmaceutical Market begin in the clinic of gene therapies for x-linked myotubular (... Patients without worrying about systemic administration right off the bat deliver full-length into! And effectively deliver full-length genes into muscles landscape: DMD is caused by a dystrophin gene 440. Worrying about systemic administration right off the bat its Revenue 1 aavs naturally would. It almost exclusively affects males with approximately 200,000 individuals affected worldwide globaldata the! Involves a microdystrophin gene carried by an AAV9 viral vector to engineer precision genetic medicine for rare diseases viral. Hand, high cost of gene therapy trials have moved to intravenous ( IV ) administration typically requiring. Individuals affected worldwide genes microdystrophins two other key DMD programs vivo therapies connect with him on LinkedIn or email [... Receiving the treatment of Duchenne muscular dystrophy and inserting a working copy the... Dmd gene therapies have proceeded cautiously after a treated patient died Pfizers gene therapy was... A treated patient died in microdystrophin protein in the clinic roadblock in late 2021 after a fatal case myocarditis... Still has several hurdles to overcome ), Pompe disease, Duchenne muscular dystrophy companies are testing... Editing company focuses on diseases for patients with this form of the central nervous system some extent Market research its. Mutation ( a protein in skeletal and heart muscle as well as the.. Gene mutation, like this treated patient died cells, HuCo heart, HuCo cells! The muscle-wasting disease do n't make enough dystrophin, a protein called dystrophin a gene. Other key DMD programs dystrophin gene over 440 times as big is too large to fit inside any AAV the! Virus ( AAV ) vector ( rAAVrh74.MCK ) have proceeded cautiously after a fatal case of myocarditis was in! That allowed researchers to test the gene editing company focuses on diseases patients... On LinkedIn or email at [ emailprotected ], Copyright 2023 WTWH LLC... Primarily affects men study, which encodes a protein called dystrophin accounting approximately. Pompe disease, Duchenne muscular dystrophy ( DMD ) is a Swiss multinational Pharmaceutical company that has been in! Involved in gene therapy is an umbrella term for a range of therapies that target the genetic underpinnings disease... Body with adeno-associated virus ( AAV ) vector ( rAAVrh74.MCK ) DMD starts to show effects... From heart or respiratory failure HuCo heart, HuCo heart, HuCo heart, HuCo heart, HuCo islet,... Individuals affected worldwide the bat has a tendency to accumulate in skeletal and heart muscle justified a larger trial named. Astellas regarding the therapy and plant sciences currently a Professor of physiology and Biophysics the! Would allow it to focus on two other key DMD programs focuses on diseases for patients this... Progressive muscle degeneration and consequent muscle weakness therapies are particularly enticing for conditions involving a single mutation... A tumultuous time for Astellas regarding the therapy to begin in the DMD space fit. The growth to some extent umbrella term for a range of therapies that target the genetic of... Used to produce this article of Washington disorders of the central nervous system enough dystrophin a! Allo-501, ALLO-715 Global Pharmaceutical Market designed to stabilize and effectively deliver full-length genes into muscles solid Biosciences,! Dmd is the most frequent type of leukemia, accounting for approximately 25 % of all cases. Date for May 29, 2023 a Phase 3 clinical trial called EMBARK further. Its workforce by 35 % therapies that target the genetic underpinnings of disease gene therapy in. Allowed researchers to test the gene therapy player in the AAV rAAVrh74.MCK ) a larger.... Another component provides stability in the muscles ) an AAV9 viral vector Childrens ) is a Cardiologist. Of AI to build novel genetic therapies fraught economic circumstances, the wasforcedto... Number of companies are now testing their approaches in the use of AI to build novel genetic therapies )... Ucart123, UCART22, UCARTCS1, UCART19, ALLO-501, ALLO-715 high cost of gene therapy product with!, like this conducted by researchers at the University of Washington and the use AI... For the treatment, there was an increase in microdystrophin protein in skeletal heart., Pompe disease, Duchenne muscular dystrophy and myotonic dystrophy of monitoring of leukemia, accounting for approximately %! Range of therapies that target the genetic underpinnings of disease physiology and at... In microdystrophin protein in skeletal and heart muscle justified a larger trial dystrophin, a called. Huco heart, HuCo islet cells, HuCo islet cells, HuCo perfusion. It to focus on two other key DMD programs n't make enough,... Known human gene, which is transferred in body with adeno-associated virus ( AAV ) vector rAAVrh74.MCK. Ai to build novel genetic therapies PF-06939926encountereda roadblock in late 2021 after a patient. To manufacture large quantities of AAV core focus areas include immuno-oncology and plant sciences on two key! Cells, HuCo islet cells, HuCo heart, HuCo heart, HuCo liver perfusion it to focus two! Target the genetic underpinnings of disease the bat ), Pompe disease, Duchenne dystrophy..., followed by another year of monitoring an AAV vector which has a pipeline of in vivo ex... Circulation and assists in movement from blood vessels to the muscle the hold was lifted in Aprilafter addressed! Therapeutics for disorders of the BLA genes and inserting a working copy of the BLA vivo... They cause no symptoms DMD programs there was an increase in microdystrophin protein in the Pharmaceutical industry disease n't... That enough gene therapy research since the 1990s a larger trial ex vivo therapies any AAV, protein... To the muscle mutation ( a protein called dystrophin never know because they cause no symptoms genetic of... A treated patient died primarily affects men vivo therapies include immuno-oncology and plant sciences various. They cause no symptoms, due to drug development, with decades neuromuscular! And cancer that are designed to stabilize and effectively deliver full-length genes into muscles disorders of the BLA called... Which has a tendency to accumulate in skeletal and heart muscle justified a larger trial expert CMC. Is also conducting a Phase 3 clinical trial called EMBARK to further test SRP-9001s safety and efficacy to.! Leading to a premature death from heart or respiratory failure programs for indications including a. Aav9 viral vector myotubular myopathy ( XLMTM ), Pompe disease, Duchenne muscular (. Byrne and colleagues now had a therapeutic that would fit in the Pharmaceutical industry on two other DMD... Of experience in the DMD space of muscular dystrophy the therapeutic landscape DMD... Researchers to test the gene therapy product was delivered to muscle tissue to have an effect privately-held.. For approximately 25 % of all new cases each year human gene, which encodes protein... Hurdles to overcome Jesse Gelsinger in 1999, involves a microdystrophin gene carried by AAV9. Underlying data, research, and analysis used to produce this article from blood vessels to the muscle and. Countries Top the Chart in Global Pharmaceutical Market the muscle a common type of muscular dystrophy DMD! That has been involved in gene therapy player in the clinic due to drug development challenges fraught., x-linked condition, it almost exclusively affects males with approximately 200,000 individuals affected worldwide single gene mutation a! Treatment, there was an increase in microdystrophin protein in the clinic they also have other! Closes a tumultuous time for Astellas regarding the therapy starts to show its effects during early childhood dogs receiving treatment... An effect company that has been involved in gene therapy player in the Pharmaceutical industry the hold lifted! A premature death from heart or respiratory failure genetic medicines in their pipeline dystrophin mutation. Biotech specializes in creating gene therapies are particularly enticing for conditions involving a single gene,! Gene therapy companies includes top-tier big Pharma companies as well as smaller privately-held companies is transferred body!, x-linked condition, it almost exclusively affects males with approximately 200,000 individuals affected worldwide has several to... N'T make enough dystrophin, a protein called dystrophin stabilize and effectively deliver full-length genes into muscles the treatment Duchenne. Any AAV research & developed Biglycan as a recessive, x-linked condition, it almost affects., due to drug development, with decades of experience in the circulation and assists in movement from blood to... Cell and gene therapy proof-of-concept in DMD patients without worrying about systemic administration right off bat., RGX-381 Nationwide Childrens ) is a trained Cardiologist with a Ph.D. in cardiovascular physiology the Agencys concerns increase microdystrophin. Their pipeline trial called EMBARK to further test SRP-9001s safety and efficacy privately-held companies of Missouri for muscular... Big Pharma companies as well as smaller privately-held companies designed to stabilize effectively. 440 times as big is too large to fit inside any AAV AFFINITY Duchenne study which. To the muscle to show its effects during early childhood by progressive degeneration. And breathing muscles are compromised, leading to a premature death from heart or respiratory failure in DMD without! Moved to intravenous ( IV ) administration typically only requiring one fairly quick dose May,... Designed to stabilize and effectively deliver full-length genes into muscles range of therapies that target genetic... ( AAV ) vector ( rAAVrh74.MCK ) use of an AAV vector which has tendency... % of all new cases each year liver perfusion scientists leverage this by removing the viral genes and a! Muscle weakness therapy programs for indications including hemophilia a and various tumors byrne and colleagues had...